CN1785240A - Dripping pills used for treating coronary heart disease and its prepn. method - Google Patents
Dripping pills used for treating coronary heart disease and its prepn. method Download PDFInfo
- Publication number
- CN1785240A CN1785240A CNA2005101242225A CN200510124222A CN1785240A CN 1785240 A CN1785240 A CN 1785240A CN A2005101242225 A CNA2005101242225 A CN A2005101242225A CN 200510124222 A CN200510124222 A CN 200510124222A CN 1785240 A CN1785240 A CN 1785240A
- Authority
- CN
- China
- Prior art keywords
- powder
- radix
- temperature
- haematitum
- medicated powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A dripping pill for treating coronary heart disease is prepared from 12 Chinese-medicinal materials including musk, pearl, notoginseng, borneol, etc. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of drop pill that is used for the treatment of coronary disease disease of ZANG-organs class and preparation method thereof.
Background technology
Coronary heart disease is because its sickness rate height, the mortality rate height, serious harm human healthy, thereby b referred to as " the first human killer ".
Cause of coronary heart disease increases with the growth at age, and degree also increases the weight of with the growth at age.There is data to show, from beginning in 40 years old, every increase by 10 years old, prevalence of coronary heart disease increases 1 times.Male 50 years old, women are after 60 years old, and the coronary atherosclerosis development is rapider, and the danger of same myocardial infarction also increases with advancing age.
World Health Organization (WHO) is classified as follows coronary heart disease: the heart failure in primary cardiac all standing, angina pectoris, myocardial infarction, the ischemic heart desease, arrhythmia.Though coronary heart disease the middle age with sequela, pathological changes coronarius also can originate from the childhood.
In most countries flourishing countries of some industry particularly, since the forties, evidence of coronary heart diseases and ultimate mortality table have revealed tangible rising.The U.S. has noticed this problem in 20 years after the fifties, strengthened research, and cardiopathic age high speed death is descended year by year, in the period of 1971～1978, descend 2.5% every year on average, descended 31.8% to 1981 annual death rate, but still had every year 550000 people to die from coronary heart disease.Secondly, as states such as Australia, New Zealand, Canada and Philippine,, decline is in various degree arranged also from the fifties.Yet the part East European countries, this index but rose in the same period, and ascensional range is 49%～90%, rises the most remarkable with Romania.According to the WHO data, China city 1960～1963 years with heart disease be the cause of the death be 36.05～52.0/10 ten thousand, and rose to 113.13～130.67/10 ten thousand in 1974～1978 years; The same period, the rural area was 111.14～151.79/10 ten thousand.Ascendant trend is year by year arranged.The various hearts in China some areas, cerebrovascular mortality rate (1,/10 ten thousand)
Occupation distributes: the chance of brain worker's incidence of coronary heart disease is high than physical labourer, and morbidity is higher in the professional population that often is in psychentonia and attention high concentration.The ratio of brain worker and physical labourer morbidity is about 2: 1.
Race difference: primary disease has tangible race difference.Contrast between country, China, Japan etc. are far low through American-European countries.In China, the prevalence of nationality such as Kazak, Tibetan, illiteracy is with regional Han nationality height; Guizhou Miao ethnic group, the Bouyei are starkly lower than local Han nationality.Difference between nationality may be relevant with concentration with trace element kind in diet situation, labor intensity, living habit, water hardness and the water.
For these reasons, study a kind of safe, medicine is effective effectively and rapidly.
This type of Chinese patent medicine of CHANSHE JIUXIN WAN has coronary artery dilator, improves myocardial oxygen delivery, and the common drug of cardiac function enhancing is wherein fast with curative effect, and the drop pill of taking convenience is an optimum selection.In the prior art; the CHANSHE JIUXIN WAN oral formulations is the watered pill; in the 7th 207 pages in " ministry standard " Chinese traditional patent formulation preparation; crude drug Margarita, Radix Salviae Miltiorrhizae extract and the Haematitum pulverize separately of " CHANSHE JIUXIN WAN " of record in will writing out a prescription becomes fine powder; Radix Ginseng Rubra and Radix Notoginseng are pulverized and add the Fel Sus domestica unguentum mixing by amount; be ground into fine powder; Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis are ground into fine powder; with above-mentioned powder facing-up except that Haematitum, sieve mixing; with water pill; bag Haematitum clothing, drying, promptly.Per hundred heavy 2g of powder coating ball.This preparation is to be the watered pill, and this preparation manipulation is harder to tackle, to its finished product drug content and the difficult control of dissolve scattered time limit, easily causes microbial contamination in the operating process.Its raw material powder is broken into fine powder, but can not be meticulous, looses otherwise can influence the molten of pill.This has just influenced the curative effect of this medicine.
Summary of the invention
Technical problem to be solved by this invention is to overcome the deficiencies in the prior art, a kind of drop pill for the treatment of coronary heart disease is provided, this drop pill more means the patient and accepts, the dispersion of medicine in substrate is the crystallization of micropowder shape, and this drop pill has advantages such as bioavailability height, evident in efficacy, taking convenience, preparation technology be simple and direct.
Technical problem to be solved by this invention realizes by following technological approaches:
A kind of drop pill for the treatment of the coronary heart disease class is prepared from by following method:
1) take by weighing each raw material by following weight portion:
Calculus Bovis 90～110, Moschus 8～11, Margarita 350～450, Venenum Bufonis 90～110, Radix Ginseng Rubra 50～70, Radix Notoginseng 250～350, Borneolum Syntheticum 90～110, Fel Sus domestica unguentum 90～110, Radix Rumicis 8～12, Haematitum 45～55, Cornu Bubali concentrate 90～110, Radix Salviae Miltiorrhizae extract 90～110;
2) get Margarita, Radix Salviae Miltiorrhizae extract and Haematitum pulverize separately and become fine powder, medicated powder is standby.
3) Radix Ginseng Rubra and Radix Notoginseng are pulverized and add the Fel Sus domestica unguentum mixing by amount, are ground into impalpable powder, with step 2) standby medicated powder facing-up except that Haematitum, sieve, it is standby to get medicated powder;
4) Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis are ground into fine powder after; the Polyethylene Glycol that adds 80 ℃; (Polyethylene Glycol: medicated powder 7: 3), after stirring, add the facing-up powder of step 3) again after; mixing; airtight and insulation splashes in 10 ℃～15 ℃ the liquid paraffin at 80 ℃, with the drop pill drop that is shaped to the greatest extent and the erasing liquor paraffin body; bag Haematitum clothing, promptly.
In the above-mentioned preparation method, wherein said impalpable powder refers to and can all sieve by No. eight, and contains and can be no less than 95% powder by No. nine sieves; Fine powder refers to can be all by No. six sieves, and contain and can be no less than 95% powder by No. seven sieves; Preferably each step medicated powder total amount is mixed with 80 ℃ the Polyethylene Glycol part by weight by 3: 7 in the step 4); Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis powder at first mix with Polyethylene Glycol; the temperature of airtight insulation is preferably 80 ℃; preferably splash in 12 ℃ the liquid paraffin, the temperature on condensed fluid top is remained on 37 ℃, the temperature of condensed fluid is controlled to be 12 ℃.
Here it is necessary that the said Chinese medicine of will writing out a prescription is ground into fine powder, be ground into fine powder and be ground into fine powder and compare through evidence, medicine can fully be dissolved in the substrate, its uniformity and dissolution rate are increased, medicine performance drug effect is rapider, bioavailability is higher, and drop pill smooth surface, the rounding made; In addition, a few flavor medicines that are ground into fine powder are expensive thin medical material, are ground into fine powder, all are necessary from the absorption and the economic angle of medicine; It also is necessary at last Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis powder at first being mixed with Polyethylene Glycol; this is to be difficult for being exposed in the air for a long time because of Moschus, Venenum Bufonis, Borneolum Syntheticum; in order to avoid the minimizing content of effective, moreover direct labor and production environment also be difficult for.
At 80 ℃, and the temperature on liquid coolant top remains on 37 ℃ with medicinal liquid insulation, and the temperature of condensed fluid is 12 ℃, and the drop pill of making through evidence does not have crystallization separates out, and no conditions of streaking and roundness are good.
Drop pill preparation process of the present invention is simple and direct, cost is low, is guaranteeing that " CHANSHE JIUXIN WAN " with the ministry standard regulation has on the basis of identical functions, also is better than this " CHANSHE JIUXIN WAN " on the curative effect of medicine and bioavailability.The angina pectoris that drop pill of the present invention causes coronary heart disease, uncomfortable in chest, breathe hard and disease such as dizzy, have coronary artery dilator, improve myocardial oxygen delivery, the effect of cardiac function enhancing.Compare with " the toad Moschus moschiferous is rescued ball ", its clinical efficacy and bioavailability obviously improve.
Further describe beneficial effect of the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit the scope of the invention.
The specific embodiment
[embodiment 1]
Take by weighing each raw material: Calculus Bovis 100g, Moschus 10g, Margarita 400g, Venenum Bufonis 100g, Radix Ginseng Rubra 60g, Radix Notoginseng 300g, Borneolum Syntheticum 100g, Fel Sus domestica unguentum 100g, Radix Rumicis 10g, Haematitum 50g, Cornu Bubali concentrate 100g, Radix Salviae Miltiorrhizae extract 100g; Get Margarita, Radix Salviae Miltiorrhizae extract and Haematitum pulverize separately and become fine powder, Radix Ginseng Rubra and Radix Notoginseng are pulverized also and add the Fel Sus domestica unguentum mixing by amount, are ground into impalpable powder, with above-mentioned powder facing-up except that Haematitum, sieve; After Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis be ground into fine powder; the Polyethylene Glycol that adds 80 ℃; (Polyethylene Glycol: medicated powder 7: 3), after stirring, add the facing-up powder except that Haematitum again after; mixing; airtight and insulation splashes in 10 ℃～15 ℃ the liquid paraffin at 80 ℃, with the drop pill drop that is shaped to the greatest extent and the erasing liquor paraffin body; bag Haematitum clothing, promptly.
[embodiment 2]
Take by weighing each raw material: Calculus Bovis 90g, Moschus 8g, Margarita 350g, Venenum Bufonis 90g, Radix Ginseng Rubra 50g, Radix Notoginseng 250g, Borneolum Syntheticum 90g, Fel Sus domestica unguentum 90g, Radix Rumicis 8g, Haematitum 40g, Cornu Bubali concentrate 190g, Radix Salviae Miltiorrhizae extract 90g; Get Margarita, Radix Salviae Miltiorrhizae extract and Haematitum pulverize separately and become fine powder, Radix Ginseng Rubra and Radix Notoginseng are pulverized also and add the Fel Sus domestica unguentum mixing by amount, are ground into impalpable powder, with above-mentioned powder facing-up except that Haematitum, sieve; After Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis be ground into fine powder; the Polyethylene Glycol that adds 80 ℃; (Polyethylene Glycol: medicated powder 7: 3), after stirring, add the facing-up powder except that Haematitum again after; mixing; airtight and insulation splashes in 10 ℃～15 ℃ the liquid paraffin at 80 ℃, with the drop pill drop that is shaped to the greatest extent and the erasing liquor paraffin body; bag Haematitum clothing, promptly.
[embodiment 3]
Take by weighing each raw material: Calculus Bovis 110g, Moschus 12g, Margarita 450g, Venenum Bufonis 110g, Radix Ginseng Rubra 70g, Radix Notoginseng 350g, Borneolum Syntheticum 110g, Fel Sus domestica unguentum 110g, Radix Rumicis 12g, Haematitum 60g, Cornu Bubali concentrate 110g, Radix Salviae Miltiorrhizae extract 110g; Get Margarita, Radix Salviae Miltiorrhizae extract and Haematitum pulverize separately and become fine powder, Radix Ginseng Rubra and Radix Notoginseng are pulverized also and add the Fel Sus domestica unguentum mixing by amount, are ground into impalpable powder, with above-mentioned powder facing-up except that Haematitum, sieve; After Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis be ground into fine powder; the Polyethylene Glycol that adds 80 ℃; (Polyethylene Glycol: medicated powder 7: 3), after stirring, add the facing-up powder except that Haematitum again after; mixing; airtight and insulation splashes in 10 ℃～15 ℃ the liquid paraffin at 80 ℃, with the drop pill drop that is shaped to the greatest extent and the erasing liquor paraffin body; bag Haematitum clothing, promptly.
The test example:
One, curative effect determinate standard
(1) curative effect of disease criterion
1. cardinal symptom such as produce effects angina pectoris disappears or reaches the produce effects standard, and electrocardiogram returns to normal ECG or reaches roughly normal (being electrocardiogram normal range)
2. effectively cardinal symptom such as angina pectoris alleviates or reaches effective standard, and electrocardiogram improves effective standard that reaches.
3. cardinal symptom such as invalid angina pectoris does not have improvement, and electrocardiogram is basic preceding identical with treatment.
4. increasing the weight of cardinal symptom such as angina pectoris and electrocardiogram increases the weight of before the test.
When comprehensive therapeutic effect is judged,, should be comprehensive therapeutic effect with the low result of curative effect if when cardinal symptom curative effect such as angina pectoris and ECG curative effect are inconsistent.
(2) tcm syndrome curative effect determinate standard
1. produce effects clinical symptoms, sign are obviously improved, and the syndrome integration reduces 〉=70%.
2. effectively clinical symptoms, sign all take a favorable turn, and the syndrome integration reduces 〉=30%.
3. invalid clinical symptoms, sign do not have obvious improvement, even increase the weight of, the syndrome integration reduces not enough＜30%.
4. increasing the weight of clinical symptoms, sign all has and increases the weight of, and the syndrome integration reduces not enough＜0.
(3) cardinal symptom criterion (curative effect to treat angina pectoris criterion is with reference to therapy of combining Chinese and Western medicine angina pectoris in 1979 and arrhythmia forum " angina pectoris and ECG curative effect criterion " in JIUYUE, 1979 Shanghai)
1. slight
(1) produce effects transference cure or basic the disappearance.
(2) effectively pain attack times, degree and persistent period have obviously and alleviate.
(3) invalid symptom is preceding identical with treatment substantially.
(4) aggravate the pain attack times, degree and persistent period increased the weight of the standard of " moderate ", " severe " (or reach) to some extent
2. moderate
(1) produce effects transference cure or basic the disappearance.
(2) effective sx is to the standard of " slightly ".
(3) invalid symptom is preceding identical with treatment substantially.
(4) aggravate the pain attack times, degree and persistent period all increased the weight of the standard of (or reach " severe ") to some extent.
3. severe
(1) the produce effects symptom disappears substantially or is relieved to the standard of " slightly ".
(2) effective sx is to the standard of " moderate ".
(3) invalid symptom is preceding identical with treatment.
(5) aggravate the pain attack times, degree and persistent period all increases the weight of to some extent.
(4) mainly detect the curative effect determinate standard (ECG curative effect criterion is with reference to therapy of combining Chinese and Western medicine angina pectoris in 1979, arrhythmia forum " angina pectoris and ECG curative effect criterion " in JIUYUE, 1979 Shanghai) of index
(1) the produce effects electrocardiogram returns to " roughly normal " (promptly " normal range) or reaches " normal ECG ".
(2) the effectively reduction of S-T section more than rise 0.05mV after treating, but does not reach normal level, and (reaching 25% above person) shoals at the negative T wave that mainly leads: or the T ripple becomes uprightly chamber or intraventricular block improver by smooth.
(3) invalid electrocardiogram is preceding identical with treatment substantially.
(4) increase the weight of the S-T section and reduce more than the 0.05mV before the treatment, it is smooth to flatten at mainly lead negative T wave intensification (reaching more than 25%) or upright T ripple, and smooth T ripple is inverted, and ectopic cardiac rhythm, atrioventricular block or intraventricular block occur.
(5) treatment angina pectoris active remedy evaluation criteria
(1) disappeared or basic the alleviation with interior (containing 3 minutes) angina pectoris in 3 minutes after the produce effects medication.
(2) angina pectoris in 3-5 minute disappears or basic the alleviation after effective medication.
(3) after the invalid medication more than 5 minutes angina pectoris alleviate gradually or do not have an improvement.
(4) increase the weight of medication after angina pectoris increase the weight of.
When observing active remedy, each case medication number of times can not be less than 10 times, can not use other drug and Therapeutic Method simultaneously.
Two, pharmacodynamics test research
Supply the reagent thing: the drop pill that the present invention is prepared.
Positive control medicine: CHANSHE JIUXIN WAN, Pan Shoude, product batch number 200503101.
1, to blood pressure, heart rate and Electrocardiographic influence: behind the laboratory animal gastric infusion, with pentobarbital sodium (30mg/kg) intravenous anesthesia, tracheal intubation, connect artificial respirator, open breast, separate LCA and aortic root, place the electromagnetic flowmeter probe, do not measure coronary flow and cardiac output respectively.Left ventricle tip intubate connects pressure transducer.Separate femoral artery, intubate is measured arterial pressure, places this crosslinking electrode of cardiogram limb, and the accurate II of mark leads electrocardiogram.
Experiment is divided into 3 groups: matched group CHANSHE JIUXIN WAN (5.4mg), the heavy dose of group of toad Moschus moschiferous heart disease curing drop pill (6.6mg), toad Moschus moschiferous heart disease curing drop pill small dose group (2.2mg).Art finishes, and treats the preceding value of the stable back of observation index record medicine, 1,3,5,10,15,20,30 minute record behind gastric infusion.
The result shows: heavy dose of group blood pressure and decreased heart rate speed are better than matched group, and low dose of effect is not obvious.
2, coronary artery dilator, improve the effect of myocardial oxygen delivery:
Influence to normal isolated rat heart function:
Experiment is divided into dosage group (4.4mg), toad Moschus moschiferous heart disease curing drop pill small dose group (2.2mg) in four groups _ blank group, the heavy dose of group of toad Moschus moschiferous heart disease curing drop pill (6.6mg), the toad Moschus moschiferous heart disease curing drop pill at random with rat
Adopt improvement Song Shifa according to the rat heart perfusion device.After heart is fixed on the perfusion device, promptly carried out physiology K-H liquid perfusion 10-15 minute, recorded heart rate (HR), shrinkage amplitude (AC) and arteria coronaria flow indexs such as (CBF) are as contrasting before the administration, change to the pastille perfusate, every index of 5,10,15,20 and 30 minutes behind the record medicine.The normal isolated rat heart coronary flow of the heavy dose of obviously increase of toad Moschus moschiferous heart disease curing drop pill as a result is obvious dose-effect relationship.5 minutes effect peakings compare P＜0.01 with matched group behind the medicine.And the effect of certain decreased heart rate is arranged, shrinkage amplitude is not seen obvious effect.
Three, pharmacological action
Calculus Bovis, Moschus, Radix Notoginseng, Venenum Bufonis, Borneolum Syntheticum have causing resuscitation with aromatic drugs, blood circulation promoting and blood stasis dispelling function in this product side, and expansible coronary artery improves myocardial oxygen delivery, and cardiac function enhancing is mainly used in angina pectoris, chest pain that coronary heart disease causes, disease such as breathe hard.
The Calculus Bovis eliminating phlegm of having one's ideas straightened out in the side is for controlling the medicine of the heart; The Moschus blood circulation promoting and dispersing pathogen accumulation of having one's ideas straightened out is treated " trusted subordinate's sudden pain ", " can lead to the unfavorable of all keys, open the heap soil or fertilizer over and around the roots of meridians and hold back " (Compendium of Material Medica); The bitter temperature of Radix Notoginseng abnormal smells from the patient, " can in its blood stasis of blood systemization " (" book on Chinese herbal medicine be looked for the truth "); Margarita tranquilizing mind, bob expectorant are apt to control the palpitation with fear palpitation with a distress feeling; The Borneolum Syntheticum causing resuscitation with aromatic drugs, " property is apt to away scurry, and atresia does not reach, so main trusted subordinate's pathogen " (" Bencao Jingshu ").All medicines share, and play the function of causing resuscitation with aromatic drugs, blood circulation and channel invigorating altogether, make the heart arteries and veins must be logical, and blood stasis must go, pained healing.
Four, clinical research
This product proves that through clinical research instructions of taking is oral, one time 2～3,3 times on the one.
To curative effect to treat angina pectoris obvious effective rate 45%, total effective rate 95%; Obvious effective rate 21.7%, total effective rate 79.9%.ECG curative effect: obvious effective rate 35%, total effective rate 72.5%.
Clinical trial observed result explanation, the angina pectoris that drop pill of the present invention causes coronary heart disease, uncomfortable in chest, breathe hard and disease such as dizzy all has significant curative effect, and curative effect is better than the positive control medicine.
Claims (4)
1, plant the preparation method of the drop pill of treatment coronary heart disease class, step is as follows:
1) take by weighing each raw material by following weight portion:
Calculus Bovis 90～110, Moschus 8～11, Margarita 350～450, Venenum Bufonis 90～110, Radix Ginseng Rubra 50～70, Radix Notoginseng 250～350, Borneolum Syntheticum 90～110, Fel Sus domestica unguentum 90～110, Radix Rumicis 8～12, Haematitum 45～55, Cornu Bubali concentrate 90～110, Radix Salviae Miltiorrhizae extract 90～110;
2) get Margarita, Radix Salviae Miltiorrhizae extract and Haematitum pulverize separately and become fine powder, medicated powder is standby.
3) Radix Ginseng Rubra and Radix Notoginseng are pulverized and add the Fel Sus domestica unguentum mixing by amount, are ground into impalpable powder, with step 2) standby medicated powder facing-up except that Haematitum, sieve, it is standby to get medicated powder;
4) Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and Radix Rumicis are ground into fine powder after; add in 80 ℃ the Polyethylene Glycol; (Polyethylene Glycol: medicated powder 7: 3), after stirring, add the facing-up powder of step 3) again after; mixing; airtight and insulation splashes in 10 ℃～15 ℃ the liquid paraffin at 80 ℃, with the drop pill drop that is shaped to the greatest extent and the erasing liquor paraffin body; bag Haematitum clothing, promptly.
2, in accordance with the method for claim 1, it is characterized in that: in the step 4) with 80 ℃ Polyethylene Glycol: medicated powder mixes by 7: 3 part by weight, and medicated powder is meant 3) step medicated powder and 4) gross weight of fine powder of step.
3, in accordance with the method for claim 1, it is characterized in that: will at first add in the Polyethylene Glycol after Calculus Bovis, Moschus, Venenum Bufonis, Pulvis Cornus Bubali Concentratus, Borneolum Syntheticum and the Radix Rumicis pulverizing in the step 4).
4, in accordance with the method for claim 1, it is characterized in that: the temperature of the airtight insulation of step 4) is 80 ℃, splashes into temperature and is in 12 ℃ the liquid paraffin, and the temperature on condensed fluid top is controlled at 37 ℃, and the temperature of condensed fluid is controlled to be 12 ℃.After the mixing, the temperature of airtight insulation is 80 ℃, splashes into temperature and is in 12 ℃ the liquid paraffin, and the temperature on condensed fluid top is controlled at 37 ℃, and the temperature of condensed fluid is controlled to be 12 ℃.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101242225A CN100382810C (en) | 2005-11-29 | 2005-11-29 | Dripping pills used for treating coronary heart disease and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101242225A CN100382810C (en) | 2005-11-29 | 2005-11-29 | Dripping pills used for treating coronary heart disease and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785240A true CN1785240A (en) | 2006-06-14 |
| CN100382810C CN100382810C (en) | 2008-04-23 |
Family
ID=36782909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101242225A Active CN100382810C (en) | 2005-11-29 | 2005-11-29 | Dripping pills used for treating coronary heart disease and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100382810C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411735B (en) * | 2008-12-05 | 2011-10-26 | 大连美罗中药厂有限公司 | Quality control method of pharmaceutical composition for preventing and treating coronary heart disease |
| CN103735618A (en) * | 2013-12-30 | 2014-04-23 | 雷允上药业有限公司 | Traditional Chinese medicine composition for treating sick sinus syndrome, coronary heart disease angina and arrhythmia and preparation method and application thereof |
| CN104055846A (en) * | 2014-07-11 | 2014-09-24 | 珠海安生凤凰制药有限公司 | Toad venom-musk Jiuxin dropping pill and preparation method thereof |
-
2005
- 2005-11-29 CN CNB2005101242225A patent/CN100382810C/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411735B (en) * | 2008-12-05 | 2011-10-26 | 大连美罗中药厂有限公司 | Quality control method of pharmaceutical composition for preventing and treating coronary heart disease |
| CN103735618A (en) * | 2013-12-30 | 2014-04-23 | 雷允上药业有限公司 | Traditional Chinese medicine composition for treating sick sinus syndrome, coronary heart disease angina and arrhythmia and preparation method and application thereof |
| CN103735618B (en) * | 2013-12-30 | 2017-10-31 | 雷允上药业集团有限公司 | It is a kind of to treat sinus syndrome and coronary disease and angina pectoris, the Chinese medicine composition of arrhythmia cordis and its preparation method and application |
| CN104055846A (en) * | 2014-07-11 | 2014-09-24 | 珠海安生凤凰制药有限公司 | Toad venom-musk Jiuxin dropping pill and preparation method thereof |
| CN104055846B (en) * | 2014-07-11 | 2018-01-05 | 珠海安生凤凰制药有限公司 | Toad musk deer heart disease curing drop pill and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100382810C (en) | 2008-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1247241C (en) | Liuwei Dihuang dripping pills and its preparation | |
| CN100382810C (en) | Dripping pills used for treating coronary heart disease and its prepn. method | |
| CN101045110A (en) | Medicine composition for treating deficiency of the kidney and its preparing method | |
| CN1297288C (en) | Medicine for treating cardiovascular disease, and its prepn. method | |
| CN1692936A (en) | Large specification Liuweidihang dripping pills contg. glutinous rehmannia and five other herb medicines, and its prepn. method | |
| CN1899410A (en) | Medicine for treating cardiovascular disease and its preparing method and quality control method | |
| CN1140289C (en) | Gynopathy treating Chinese medicine with functions of diminishing inflammation and eliminating spot and its prepn | |
| CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN103720810A (en) | Medicine for treating qi-stagnation and blood stasis coronary heart disease and complication of disease and preparation method of medicine | |
| CN107551217B (en) | Formula of traditional Chinese medicine composition for treating chronic heart failure by promoting expression of sarcoplasmic reticulum calcium pump | |
| CN115844972B (en) | Navel patch for treating osteoporosis and preparation method thereof | |
| US11684631B2 (en) | Method of treating cancer with composition of traditional Chinese medicine and its preparation method thereof | |
| CN102008539A (en) | Medicinal composition for treating diseases such as vital myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN1895341A (en) | Chinese-medicinal preparation for treating cardiovascular and cerebrovascular diseases | |
| CN100345587C (en) | Medicine for treating aural dizziness and cervical dizziness and its prepn process | |
| CN1255108C (en) | Prepn process of Xuesaitong guttate pills | |
| CN1813855A (en) | Medicine for treating cardio-cerebrovascular disease | |
| CN1679677A (en) | Danqi drops for activating blood and eliminating blood stasis and preparation thereof | |
| CN1504231A (en) | Medicine for tumour | |
| CN1651067A (en) | Medicinal composition for treating and/or preventing heart brnin blood vessel disease and its preparation method | |
| CN1281237C (en) | Radiation-proof frost-like powder for beauty white and dispelling speckle | |
| CN1593574A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1583041A (en) | Tongmai drops and their preparation | |
| CN101843835B (en) | Chinese medicament for treating coronary diseases | |
| CN105687571A (en) | Metoprolol containing pharmaceutical composition for treating hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |